Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have ...

BridgeBio (BBIO) rose 6.6% after a court filing disclosed a settlement in a generic patent case over Pfizer's (PFE) Vyndamax ...

Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.

Pfizer (NYSE:PFE) has agreed to acquire Metsera (NASDAQ:MTSR) in a deal worth $47.50 per share in cash, valuing the company at $4.9 billion upfront, with the potential for shareholders to receive up ...

“Obesity is a large and growing space with over 200 health conditions associated with it. The proposed acquisition of Metsera aligns with our focus on directing our investments to the most impactful ...

Pfizer's COVID Vaccine for Kids Under 5 , Moves Closer to FDA Approval . Pfizer announced on June 1 that its application to the Food and Drug Administration (FDA) for the vaccine was complete. Pfizer ...

Known as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still searching for ...

(Reuters) -Pfizer filed a second lawsuit on Monday accusing Danish drugmaker Novo Nordisk of structuring its $9 billion bid for Metsera to stall the entry of the biotech firm's treatments into the ...

Pfizer has filed a lawsuit against Metsera, Metsera’s board of directors and Novo Nordisk, claiming they breached a merger agreement. The lawsuit, filed in the U.S. District Court for the District of ...

Intent on growing its leading position in obesity and weight management drugs, Novo Nordisk has made an unsolicited, approximately up-to-$9 billion bid for Metsera—more than a month after Pfizer ...